The CJC-1295 and Ipamorelin Stack: What the Research Actually Describes

The pairing of CJC-1295 and Ipamorelin is one of the most frequently discussed combinations among growth hormone (GH) secretagogues studied in research settings. The two peptides belong to different pharmacological classes but share a common downstream goal: influencing the pituitary gland's release of endogenous growth hormone. Rather than introducing synthetic growth hormone directly, both compounds are studied as agents that prompt the body's own somatotroph cells to secrete GH.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that normally signals the pituitary to produce GH. Ipamorelin is a small pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHSR), the same receptor targeted by the natural hormone ghrelin. Because each peptide engages a separate receptor, researchers have examined whether combining them produces a more pronounced physiological response than either alone.

This combination is sometimes sold as a pre-mixed blend and sometimes as two separate vials. The scientific rationale for studying them together rests on decades of endocrinology research showing that GHRH and GH secretagogues interact in a complementary way. Foundational work on individual GHRH analogs and on selective secretagogues like Ipamorelin has been published in peer-reviewed journals, though studies of the specific two-peptide protocol in humans remain limited.

It is important to frame this topic accurately from the outset. Neither CJC-1295 nor Ipamorelin is approved as a medicine by the U.S. Food and Drug Administration or the European Medicines Agency. Both are handled as research chemicals. This guide summarizes what the published literature describes about mechanism, timing, formulation differences, and documented adverse effects. It does not recommend any dose, and it is not a substitute for medical advice. If you are considering anything related to these compounds, consult a qualified healthcare professional and review our medical disclaimer.

For readers new to combining research peptides, our overview of peptide stacking explains the general principles that make certain pairings a subject of scientific interest.

CJC-1295 is built on the first 29 amino acids of native GHRH, the sequence known to retain the full biological activity of the parent hormone. Native GHRH is released from the hypothalamus in pulses and travels to the anterior pituitary, where it binds the GHRH receptor on somatotroph cells and stimulates both the synthesis and the release of growth hormone. The problem with unmodified GHRH as a research tool is its extremely short half-life: enzymes in the blood, particularly dipeptidyl peptidase-4 (DPP-4), degrade it within a couple of minutes.

To address this, the CJC-1295 sequence (also called Mod GRF 1-29 in its short-acting form) incorporates four amino acid substitutions that make the molecule more resistant to enzymatic breakdown. These substitutions preserve receptor binding while slowing degradation. The result is a GHRH analog that maintains activity substantially longer than native GHRH.

A defining feature of GHRH-based signaling is that it works with the body's own regulatory feedback rather than overriding it. GH release driven by a GHRH analog is still modulated by somatostatin, the inhibitory hormone that suppresses GH secretion. Research by Ionescu and Frohman demonstrated that even during continuous stimulation by CJC-1295 with DAC, GH continued to be secreted in a pulsatile pattern rather than as a flat, continuous elevation. This preservation of pulsatility is often cited as a reason GHRH analogs are studied as more physiological tools than exogenous GH itself.

In the clinical pharmacology study by Teichman and colleagues, single doses of CJC-1295 with DAC in healthy adults produced sustained increases in circulating GH and insulin-like growth factor 1 (IGF-1), the downstream mediator of many of GH's effects. Mean GH concentrations rose several-fold, and IGF-1 remained elevated for days, reflecting the long-acting nature of the DAC formulation.

For a deeper single-molecule reference, see our dedicated CJC-1295 guide, which covers the peptide's structure and research history in more detail.

Ipamorelin belongs to a class called growth hormone-releasing peptides (GHRPs), or more broadly growth hormone secretagogues. Unlike CJC-1295, it does not act on the GHRH receptor. Instead, it binds the growth hormone secretagogue receptor (GHSR-1a), the receptor for the hormone ghrelin. Activation of this receptor triggers GH release through a signaling cascade that is distinct from, and complementary to, the GHRH pathway.

Ipamorelin was first described in a landmark 1998 paper by Raun and colleagues, who characterized it as the first selective growth hormone secretagogue. Selectivity is the key word. Earlier secretagogues such as GHRP-6 and GHRP-2 stimulated GH but also raised levels of other hormones, notably cortisol, adrenocorticotropic hormone (ACTH), and prolactin. In the original animal and in vitro work, Ipamorelin released GH with a potency comparable to GHRP-6 but, at doses that stimulated GH, did not produce the significant increases in cortisol and prolactin seen with the earlier compounds.

Structurally, Ipamorelin is a small pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) with a molecular weight of about 711.85 g/mol, far smaller than the 29-amino-acid CJC-1295. Its GH-releasing action is dose-dependent and, like the natural ghrelin system, it works partly by amplifying GH pulses and partly by acting on the same somatotroph cells that respond to GHRH.

An additional feature described in the literature is that GHSR agonists can suppress somatostatin tone at the level of the pituitary and hypothalamus. Since somatostatin is the brake on GH release, reducing its inhibitory effect while simultaneously pushing on the accelerator is central to how secretagogues amplify a GH pulse. This dual action, less brake and more accelerator, becomes especially relevant when Ipamorelin is studied alongside a GHRH analog.

Because the ghrelin receptor is also involved in appetite signaling, some secretagogues are associated with increased hunger. Ipamorelin is generally described as having a comparatively modest effect on appetite relative to more potent ghrelin mimetics, though individual responses in research reports vary.

The core reason CJC-1295 and Ipamorelin are studied together is synergy at the level of the GH pulse. Because a GHRH analog and a GH secretagogue act through two separate receptors and two separate intracellular signaling pathways, their combined effect on GH release has been repeatedly described in endocrinology research as greater than the simple sum of the two given individually.

Three mechanisms are typically cited to explain this synergy. First, GHRH (via CJC-1295) increases the number of somatotroph cells that are primed and ready to release GH, effectively enlarging the releasable pool. Second, the GHSR agonist (Ipamorelin) triggers the actual release and does so through a calcium-dependent pathway that differs from the GHRH pathway, so the two signals reinforce one another inside the cell. Third, the secretagogue helps blunt somatostatin, the inhibitory hormone, so the GHRH signal meets less resistance.

The net picture that emerges from the literature on GHRH-plus-secretagogue combinations is a larger amplitude GH pulse than either compound produces alone. This principle predates CJC-1295 and Ipamorelin specifically; it was established in earlier studies pairing GHRH with GHRP-6 and GHRP-2, and it is the pharmacological logic that the modern stack inherits.

A second, more practical reason the two are paired is complementary kinetics and selectivity. Ipamorelin provides a sharp, selective pulse with minimal reported impact on cortisol and prolactin, while CJC-1295 provides the sustained GHRH tone that keeps the somatotrophs responsive. Combining them is intended, in research terms, to mimic the natural interplay between hypothalamic GHRH and ghrelin signaling more closely than either agent alone.

It is worth stressing what remains unproven. Much of the synergy data comes from acute studies measuring GH and IGF-1 levels, not from long-term controlled trials measuring clinical outcomes such as body composition, recovery, or safety over months in humans. The mechanistic rationale is well documented; the long-term human outcome data for this specific pairing is not. Readers should treat claims about body composition or anti-aging benefits as hypotheses drawn from mechanism, not established results. This content is for educational purposes only.

One of the most misunderstood points about CJC-1295 is that the name is used for two meaningfully different molecules. The distinction comes down to a component called the Drug Affinity Complex (DAC), and it changes the pharmacokinetics dramatically.

CJC-1295 with DAC includes a chemical linker (a maleimidopropionyl group attached through a lysine residue) that binds covalently to circulating serum albumin shortly after administration. Albumin is an abundant, long-lived blood protein, so by hitching a ride on it, the peptide is protected from rapid enzymatic degradation and renal clearance. This extends the functional half-life to roughly 6 to 8 days. In the study by Teichman and colleagues, a single injection of CJC-1295 with DAC raised GH and IGF-1 for well over a week.

CJC-1295 without DAC, commonly labeled Mod GRF 1-29, has the same four stabilizing amino acid substitutions but lacks the albumin-binding linker. Its half-life is measured in minutes rather than days, typically cited as around 30 minutes. This produces a short, sharp elevation in GHRH activity rather than a sustained plateau.

The table below summarizes the practical contrasts described in the literature.

This difference matters for the stack. When researchers pair the no-DAC form with Ipamorelin, the goal is to align two short pulses so they coincide, reinforcing a single large GH spike that respects the body's natural pulsatile rhythm. When the DAC form is used, the sustained GHRH background is present continuously, and Ipamorelin is used to trigger pulses against that elevated baseline. Some researchers express concern that the continuous elevation from the DAC form (the so-called GH bleed) departs further from natural physiology than the pulse-matched no-DAC approach. Both patterns appear in the literature, and neither is established as superior for human outcomes.

On the supply side, note that most research suppliers stock the without-DAC version of CJC-1295, so buyers should verify exactly which molecule a product contains rather than assuming from the CJC-1295 name alone.

Timing considerations for GH secretagogues are tied to two physiological facts: growth hormone is naturally released in pulses, with the largest pulse occurring during the first phase of deep sleep, and GH release is blunted by the presence of high circulating insulin and glucose. These two facts shape most of what the research and practitioner literature describes about when secretagogues are studied.

The pulsatility point explains why the short-acting no-DAC combination is often studied as a timed pulse. Because both Mod GRF 1-29 and Ipamorelin act quickly and clear quickly, aligning them produces a discrete GH spike. Practitioners frequently reference administration around bedtime to reinforce the natural nocturnal GH pulse, and multiple daily pulses have been described in the research protocol literature to mimic the several pulses the body produces across 24 hours.

The insulin point explains the frequently cited emphasis on a fasted state. Elevated blood glucose and the insulin response to a meal, particularly a carbohydrate- or fat-containing meal, can suppress the GH response to a secretagogue. This is why research descriptions commonly separate administration from food intake. The relevant window described in the literature is roughly a period without food before and after, though exact intervals vary between sources and are not standardized.

For the DAC form, timing is a different question. Because it circulates for days, the goal is not to match a single pulse but to maintain a steady GHRH background, so dosing frequency is far lower. The trade-off, as noted earlier, is that this continuous tone diverges from natural pulsatile secretion.

It is essential to be clear about what these timing observations are and are not. They describe the pharmacological rationale and patterns reported in research and practitioner sources. They are not a validated clinical protocol, and this guide deliberately provides no doses, frequencies, or specific schedules. Anyone evaluating these compounds should do so under professional medical supervision. For tracking research variables such as timing and reconstitution across a cycle, some users reference tools like our Peptide Lab reconstitution calculator and tracker.

Because human trial data on the specific CJC-1295 plus Ipamorelin stack is limited, the documented adverse effects come from a mix of the individual clinical studies, the known pharmacology of GH and IGF-1 elevation, and reported experiences with GH secretagogues as a class. Presenting these honestly, including the uncertainty, is part of an evidence-based approach.

The most commonly reported effects in the secretagogue literature are injection-site reactions (redness, itching, or swelling), transient flushing or a feeling of warmth shortly after administration, headache, and lightheadedness. Some users of GHRH analogs report a head-rush sensation attributed to the peptide's effect on blood vessels. These effects are generally described as mild and short-lived in the available reports.

A second category relates to water retention, joint discomfort, and tingling or numbness in the extremities. These are recognized effects of elevated growth hormone activity and can manifest as mild edema or carpal-tunnel-like symptoms. They reflect GH's known physiological actions and tend to be dose-related in the broader GH literature.

A third and important consideration is the effect of sustained GH and IGF-1 elevation on glucose metabolism. Growth hormone is a counter-regulatory hormone to insulin, and chronic elevation can reduce insulin sensitivity and raise blood glucose. This is a mechanistic concern with any agent that persistently increases GH, and it is one reason the continuous exposure from the DAC form draws particular caution in the literature.

Ipamorelin's selectivity is relevant here: its main documented advantage over older GHRPs is the reduced impact on cortisol and prolactin, which lowers the likelihood of the cortisol- and prolactin-related effects seen with less selective secretagogues. This does not mean it is free of effects, only that its hormonal profile is described as cleaner.

Finally, the deepest limitation is the absence of long-term human safety data for this combination. Theoretical concerns associated with sustained IGF-1 elevation, including its relationship to cellular proliferation, cannot be dismissed and have not been resolved for these research peptides. No source should describe this stack as free of risk. Anyone considering it should discuss their personal history, particularly any history of cancer, diabetes, or endocrine disorders, with a qualified clinician. This section is educational and not medical advice.

Both CJC-1295 and Ipamorelin are typically supplied as a lyophilized (freeze-dried) white powder in a sealed vial. In this dry state they are relatively stable, but they must be reconstituted into liquid form before they can be handled for any research use. Understanding reconstitution is primarily a matter of preserving peptide integrity and calculating concentration accurately.

The standard reconstitution solvent described in the peptide literature is bacteriostatic water, which is sterile water containing a small percentage of benzyl alcohol as a preservative. The benzyl alcohol allows a multi-use vial to remain usable over a period of days to weeks without significant microbial growth, which is why it is preferred over plain sterile water for peptides that will be drawn from repeatedly. Some protocols reference plain sterile water or bacteriostatic sodium chloride, but bacteriostatic water is the most common reference point.

Technique matters. The solvent should be added slowly, directed against the inner glass wall of the vial rather than sprayed directly onto the powder, because peptides are fragile and can be damaged by mechanical force. The vial should then be gently swirled, never vigorously shaken, until the powder fully dissolves. Foaming is a sign of excessive agitation and should be avoided.

Concentration is a calculation, not a guess. The final concentration depends on the amount of peptide in the vial and the volume of solvent added. Because researchers often need to work out how a given solvent volume translates into peptide per unit volume, a reconstitution calculator is commonly used to remove arithmetic error. This guide intentionally does not provide target concentrations or volumes, since those imply a dose.

Storage is the final consideration. Reconstituted peptides are generally described as requiring refrigeration at approximately 2 to 8 degrees Celsius, protected from light, and are less stable than the lyophilized powder. The dry powder itself is often stored frozen for long-term stability. Repeated temperature swings and exposure to light accelerate degradation, so minimizing time at room temperature is a recurring theme in handling guidance. When CJC-1295 and Ipamorelin are supplied as a pre-mixed blend in a single vial, the same principles apply to the combined product. Always follow the specific supplier's stated storage and handling instructions, and treat all such material as research use only.

Clear information on regulatory status is essential and often overlooked. Neither CJC-1295 nor Ipamorelin is an approved medicine. Neither has received marketing authorization from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for human therapeutic use. They are sold and handled under the label research use only, and products are typically marked as not for human consumption.

This has several practical implications. First, research chemicals are not manufactured to pharmaceutical Good Manufacturing Practice standards unless a specific supplier documents otherwise, so purity, sterility, and actual peptide content can vary between sources. Independent third-party testing (a certificate of analysis) is the main way researchers assess quality, and its absence is a meaningful red flag.

Second, legal status varies by jurisdiction. In many countries these peptides occupy a gray area: legal to sell for laboratory research but not legal to market for human use, and possession or importation rules differ from place to place. Readers are responsible for understanding the laws in their own location.

Third, both compounds are relevant to anti-doping regulations. Growth hormone secretagogues, including GHRH analogs and GHRPs, fall under the World Anti-Doping Agency (WADA) prohibited list within the peptide hormones and growth factors category. Athletes subject to testing should understand that these substances are banned in and out of competition.

The consistent throughline of this guide is that the CJC-1295 and Ipamorelin stack is a subject of scientific and pharmacological interest with a well-documented mechanistic rationale, but limited long-term human safety and outcome data. This article is provided for educational purposes only. It is not medical advice, and it does not endorse the use of these peptides. Consult a qualified healthcare professional before making any decision related to research peptides, and review our full medical disclaimer for additional context.